TRAVERE THERAPEUTICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $302.1M | $165.8M |
| FY2022 | — | $42.9M | $61.7M |
| FY2023 | — | $200.8M | $58.2M |
| FY2024 | — | $59.1M | $58.5M |
| FY2025 | — | $114.8M | $93.0M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $302.1M | $165.8M |
| FY2022 | — | $42.9M | $61.7M |
| FY2023 | — | $200.8M | $58.2M |
| FY2024 | — | $59.1M | $58.5M |
| FY2025 | — | $114.8M | $93.0M |